Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer

Akyurek, Nalan; GUZEL, Caglar; Senturk, Muhammed Ertugrul; Öztürk, Hüseyin Furkan; Eroğlu, Fatma Nazan; DINCBAS, HIDAYET FAZILET; Demircan, Niyazi Volkan; Acar, Elif; Akmansu, Muge

doi:10.5505/tjo.2022.3523

Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer

Volkan DEMİRCAN, (Mehmet Akif İnan Eğitim ve Araştırma Hastanesi, Radyasyon Onkolojisi Bölümü, Şanlıurfa, Türkiye)

Elif ACAR, (Gazi Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Muhammed Ertugrul Senturk, (Gazi Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Ankara, Türkiye)

Caglar GUZEL, (Gazi Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Ankara, Türkiye)

Fatma Nazan Eroğlu, (Atatürk Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Radyasyon Onkolojisi Bölümü, Ankara, Türkiye)

Nalan AKYÜREK, (Gazi Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Hüseyin Furkan ÖZTÜRK, (Ankara Bilkent Şehir Hastanesi, Radyasyon Onkolojisi Bölümü, Ankara, Türkiye)

H. Fazilet Öner DİNÇBAŞ, (İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, İstanbul, Türkiye)

Müge AKMANSU (Gazi Üniversitesi, Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, Ankara, Türkiye)

Türk Onkoloji Dergisi

2 1

Yıl: 2022 Cilt: 37 Sayı: 3 Sayfa Aralığı: 227 - 238 Metin Dili: İngilizce DOI: 10.5505/tjo.2022.3523 İndeks Tarihi: 05-05-2023

Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer

Öz:

The discovery of PD-L1 receptors triggered a great interest in immunotherapeutics for the management of locally advanced non-small-cell lung cancer (NSCLC). The efficacy of immunotherapeutics for overall survival (OS) in locally advanced NSCLC has been proven in several clinical trials. However, no data exist for the relationship between radiotherapy (RT) response and programmed death-ligand (PD-L1) receptor positivity in the literature. In this regard, we aimed to investigate the predictor value of PD-L1 receptors for RT response. METHODS Eighty patients who were diagnosed as having locally advanced NSCLC were selected from among patients in whom PD-L1 status was assessed in the Gazi University pathology laboratory. The relationship between PD-L1 and progression-free survival (PFS), OS, metastasis-free survival (MFS), RT response, and RT doses was evaluated using Kaplan-Meier and Cox regression analysis. Chi-square and t-tests were used for descriptive statistics. RESULTS The median follow-up was 16.1 months. The mean age was 61.1 years. PD-L1 positivity was detected in 34 patients. One year and 2-year OS and PFS ratios were found as 87%, 54% and 65%, 30%, respectively. The median OS and PFS were 26.8 and 15.1 months, respectively. There was no statistically significant difference between PD-L1 receptor status and OS and PFS (p=0.736 and p=0.372, respectively). In the PD-L1 positive subgroup analysis for OS, doses higher than 60 Gy (n=28, mean dose 64.6±1.53) were found superior to the 60 Gy dose (n=6) (p=0.034). The median MFS was 33 months. CONCLUSION PD-L1 status did not seem to be a predictor for RT response. However, despite the low number of patients in the 60 Gy group, our study howed that dose-escalation could improve survival in PD-L1 positive locally advanced NSCLC.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49
2. Sarı M, Vatansever S. Current trends in the ıncidence of non-small cell lung cancer in Turkey: Lung Cancer Aging. EJMI 2020;4(2):169–72.
3. Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database. J Clin Oncol 2006;24(18S) suppl: 384S.
4. The American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. 2017.
5. van Laar M, van Amsterdam WAC, van Lindert ASR, de Jong PA, Verhoeff JJC. Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis. Radiother Oncol 2020;151:152–75.
6. Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017;8(1):1–20.
7. Bradley JD, Hu C, Komaki RU, Masters G, Blumenschein GR, Schild SE, et al. Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy +/- cetuximab for stage III NSCLC. Int J Radiat Oncol Biol Phys 2017;99:Suppl:S105.
8. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377(20):1919–29.
9. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al; PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379(24):2342–50.
10. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, Set al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001;193(7):839–46.
11. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003;33(10):2706–16.
12. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027–34.
13. Meyers DE, Bryan PM, Banerji S, Morris DG. Targeting the PD-1/PD-L1 axis for the treatment of non-small- cell lung cancer. Curr Oncol 2018;25(4):324–34.
14. Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol 2015;41(4):450–6.
15. Wang Y, Kim TH, Fouladdel S, Zhang Z, Soni P, Qin A, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer. Sci Rep 2019;9(1):566.
16. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014;124(2):687–95.
17. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014;74(19):5458–68.
18. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018–28.
19. Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 2018;127(1):1–5.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47.
21. Sheikhbahaei S, Mena E, Marcus C, Wray R, Taghipour M, Subramaniam RM. 18F-FDG PET/CT: therapy response assessment interpretation (Hopkins Criteria) and survival outcomes in lung cancer patients. J Nucl Med 2016;57(6):855–60.
22. Yilmaz U, Yılmaz U, Yasar Z, Kıraklı EK, Ulger S, Ozdogan Y, et al. Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience. J Cancer Res Ther 2016;12(1):334–9.
23. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103(19):1452–60.
24. US National Institutes of Health. Study of pembrolizumab (MK-3475) in participants with progressive locally advanced or metastatic carcinoma, melanoma, or non-small cell lung carcinoma (P07990/MK-3475- 001/KEYNOTE-001). Available at: https://clinicaltrials. gov/ct2/show/NCT01295827. Accessed Jun 1, 2015.
25. Jeong H, Bok S, Hong BJ, Choi HS, Ahn GO. Radiationinduced immune responses: mechanisms and therapeutic perspectives. Blood Res 2016;51(3):157–63.
26. Guo L, Song P, Xue X, Guo C, Han L, Fang Q, et al. Variation of programmed death ligand 1 expression after platinum-based neoadjuvant chemotherapy in lung cancer. J Immunother 2019;42(6):215–20.
27. Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B, et al. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci 2016;107(11):1563–71.
28. Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, et al. Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small- cell lung cancer: a systematic review. JAMA Oncol 2017;3(8):1120–9.
29. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17(9):2692–9.
30. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high- -dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB nonsmall- cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16(2):187–99.
31. Belderbos J, Walraven I, van Diessen J, Verheij M, de Ruysscher D. Radiotherapy dose and fractionation for stage III NSCLC. Lancet Oncol 2015;16(4):e156–7.
32. Ma L, Men Y, Feng L, Kang J, Sun X, Yuan M, et al. A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer. Radiol Oncol 2019;53(1):6–14.

APA	Demircan N, Acar E, Senturk M, GUZEL C, Eroğlu F, Akyurek N, Öztürk H, DINCBAS H, Akmansu M (2022). Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer. , 227 - 238. 10.5505/tjo.2022.3523
Chicago	Demircan Niyazi Volkan,Acar Elif,Senturk Muhammed Ertugrul,GUZEL Caglar,Eroğlu Fatma Nazan,Akyurek Nalan,Öztürk Hüseyin Furkan,DINCBAS HIDAYET FAZILET,Akmansu Muge Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer. (2022): 227 - 238. 10.5505/tjo.2022.3523
MLA	Demircan Niyazi Volkan,Acar Elif,Senturk Muhammed Ertugrul,GUZEL Caglar,Eroğlu Fatma Nazan,Akyurek Nalan,Öztürk Hüseyin Furkan,DINCBAS HIDAYET FAZILET,Akmansu Muge Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer. , 2022, ss.227 - 238. 10.5505/tjo.2022.3523
AMA	Demircan N,Acar E,Senturk M,GUZEL C,Eroğlu F,Akyurek N,Öztürk H,DINCBAS H,Akmansu M Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer. . 2022; 227 - 238. 10.5505/tjo.2022.3523
Vancouver	Demircan N,Acar E,Senturk M,GUZEL C,Eroğlu F,Akyurek N,Öztürk H,DINCBAS H,Akmansu M Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer. . 2022; 227 - 238. 10.5505/tjo.2022.3523
IEEE	Demircan N,Acar E,Senturk M,GUZEL C,Eroğlu F,Akyurek N,Öztürk H,DINCBAS H,Akmansu M "Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer." , ss.227 - 238, 2022. 10.5505/tjo.2022.3523
ISNAD	Demircan, Niyazi Volkan vd. "Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer". (2022), 227-238. https://doi.org/10.5505/tjo.2022.3523

APA	Demircan N, Acar E, Senturk M, GUZEL C, Eroğlu F, Akyurek N, Öztürk H, DINCBAS H, Akmansu M (2022). Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer. Türk Onkoloji Dergisi, 37(3), 227 - 238. 10.5505/tjo.2022.3523
Chicago	Demircan Niyazi Volkan,Acar Elif,Senturk Muhammed Ertugrul,GUZEL Caglar,Eroğlu Fatma Nazan,Akyurek Nalan,Öztürk Hüseyin Furkan,DINCBAS HIDAYET FAZILET,Akmansu Muge Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer. Türk Onkoloji Dergisi 37, no.3 (2022): 227 - 238. 10.5505/tjo.2022.3523
MLA	Demircan Niyazi Volkan,Acar Elif,Senturk Muhammed Ertugrul,GUZEL Caglar,Eroğlu Fatma Nazan,Akyurek Nalan,Öztürk Hüseyin Furkan,DINCBAS HIDAYET FAZILET,Akmansu Muge Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer. Türk Onkoloji Dergisi, vol.37, no.3, 2022, ss.227 - 238. 10.5505/tjo.2022.3523
AMA	Demircan N,Acar E,Senturk M,GUZEL C,Eroğlu F,Akyurek N,Öztürk H,DINCBAS H,Akmansu M Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer. Türk Onkoloji Dergisi. 2022; 37(3): 227 - 238. 10.5505/tjo.2022.3523
Vancouver	Demircan N,Acar E,Senturk M,GUZEL C,Eroğlu F,Akyurek N,Öztürk H,DINCBAS H,Akmansu M Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer. Türk Onkoloji Dergisi. 2022; 37(3): 227 - 238. 10.5505/tjo.2022.3523
IEEE	Demircan N,Acar E,Senturk M,GUZEL C,Eroğlu F,Akyurek N,Öztürk H,DINCBAS H,Akmansu M "Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer." Türk Onkoloji Dergisi, 37, ss.227 - 238, 2022. 10.5505/tjo.2022.3523
ISNAD	Demircan, Niyazi Volkan vd. "Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer". Türk Onkoloji Dergisi 37/3 (2022), 227-238. https://doi.org/10.5505/tjo.2022.3523